Discovery - University of Dundee - Online Publications

Library & Learning Centre

Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial

Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial

Research output: Contribution to journalArticle

View graph of relations

Authors

  • Kelly-Anne Phillips
  • Karin Ribi
  • Zhuoxin Sun
  • Alisa Stephens
  • Alastair Thompson
  • Vernon Harvey
  • Beat Thuerlimann
  • Fatima Cardoso
  • Olivia Pagani
  • Alan S. Coates
  • Aron Goldhirsch
  • Karen N. Price
  • Richard D. Gelber
  • Juerg Bernhard

Research units

Info

Original languageEnglish
Pages388-395
Number of pages8
JournalBreast
Journal publication dateOct 2010
Volume19
Issue5
DOIs
StatePublished

Abstract

Cognitive function in postmenopausal women receiving letrozole or tamoxifen as adjuvant endocrine treatment was compared during the fifth year of treatment in a substudy of the BIG 1-98 trial. In BIG 1-98 patients were randomized to receive adjuvant (A) 5-years tamoxifen, (B) 5-years letrozole, (C) 2-years tamoxifen followed by 3-years letrozole, or (D) 2-years letrozole followed by 3-years tamoxifen. The primary comparison was the difference in composite score for patients taking letrozole (B + C: N = 65) vs. tamoxifen (A + D; N = 55). The patients taking letrozole had better overall cognitive function than those taking tamoxifen (difference in mean composite z-scores = 0.28, P = 0.04, 95% Cl: 0.02, 0.54, Cohen's D = 0.40 indicating small to moderate effect). In this substudy, breast cancer patients taking adjuvant letrozole during the fifth year of treatment had better cognitive function than those taking tamoxifen, suggesting aromatase inhibitors do not adversely impact cognition compared with tamoxifen. (C) 2010 Elsevier Ltd. All rights reserved.

Documents

Library & Learning Centre

Contact | Accessibility | Policy